Skip to main content
SpringerLink
Log in

Neuronal vulnerability in Parkinson’s disease

  • Conference paper
Advances in Research on Neurodegeneration

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURAL SUPPL,volume 50))

Summary

Although Parkinson’s disease is characterized by a loss of dopaminergic neurons in the substantia nigra not all dopaminergic neurons degenerate in this disease. This suggests that some specific factors make subpopulations of dopaminergic neurons more susceptible to the disease. Here, we show that the most vulnerable neurons are particularly sensitive to oxidative stress and rise in intracellular calcium concentrations. Because both events seem to occur in Parkinson’s disease this may explain why some dopaminergic neurons degenerate and other do not.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bogerts B, Häntsch J, Herzer M (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psych 18: 951–969

    CAS  Google Scholar 

  • Ceballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y (1990) Superoxide dismutase and Parkinson’s disease. Lancet 335 i: 1035–1036

    Article  Google Scholar 

  • Damier P, Hirsch E, Javoy-Agid F, Zhang P, Agid Y (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52: 1–6

    Article  PubMed  CAS  Google Scholar 

  • Damier P, Hirsch EC, Agid Y, Graybiel AM (1995) Pattern of cell loss in the substantia nigra in Parkinson’s disease. Soc Neurosci Abstr 21: 1250

    Google Scholar 

  • Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389

    Article  PubMed  CAS  Google Scholar 

  • Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52: 1830–1836

    Article  PubMed  CAS  Google Scholar 

  • Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson’s disease. J Neurochem 55: 16–20

    Article  PubMed  CAS  Google Scholar 

  • Earle KM (1968) Studies in Parkinson’s disease including X-ray fluorescent spectroscopy of formalin fixed tissue. J Neuropathol Exp Neurol 27: 1–14

    Article  PubMed  CAS  Google Scholar 

  • Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 32: 796–798

    Article  Google Scholar 

  • Faucheux BA, Hirsch EC, Villares J, Selimi F, Mouatt-Prigent A, Javoy-Agid F, Agid Y (1993) Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson’s disease. J Neurochem 60: 2238–2241

    Article  Google Scholar 

  • Faucheux BA, Herrero MT, Villares J, Levy R, Javoy-Agid F, Obeso JA, Hauw JJ, Agid Y, Hirsch EC (1995) Autoradiographic localization and density of [125I]ferrotrans-ferrin binding sites in the basal ganglia of control subjects, patients with Parkinson’s disease and MPTP-lesioned monkeys. Brain Res 691: 115–124

    Article  PubMed  CAS  Google Scholar 

  • Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y, Hirsch EC (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson’s disease. Proc Natl Acad Sci USA 92: 9303–9307

    Article  Google Scholar 

  • Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114: 2283–2301

    Article  PubMed  Google Scholar 

  • Hassler R (1937) Zur Normalanatomie der Substantia Nigra, Versuch einer architektonischen Gliederung. J Psychol Neurol 48: 1–55

    Google Scholar 

  • Hassler R (1938) Zur Pathologies der Paralysis Agitans und des post enzephalitischen Parkinsonismus. J Psychol Neurol 48: 387–476

    Google Scholar 

  • Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially affected in Parkinson’s disease. Nature 334: 345–348

    Article  PubMed  CAS  Google Scholar 

  • Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an x-ray microanalysis. J Neurochem 56: 446–451

    Article  PubMed  CAS  Google Scholar 

  • Hirsch EC, Mouatt A, Thomasset M, Javoy-Agid F, Agid Y, Graybiel AM (1992) Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson’s disease. Neurodegeneration 1: 83–93

    Google Scholar 

  • Ito H, Goto S, Sakamoto S, Hirano A (1992) Calbindin-D28K in the basal ganglia of patients with Parkinsonism. Ann Neurol 32: 543–550

    Article  PubMed  CAS  Google Scholar 

  • Iwamoto N, Thangnipon W, Crawford C, Emson PC (1991) Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer’s disease. Brain Res 561: 177–180

    Article  PubMed  CAS  Google Scholar 

  • Jellinger K, Paulus W, Grundke-Iqbal I (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm 2: 327–340

    Article  CAS  Google Scholar 

  • Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MB (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168–1171

    Article  PubMed  CAS  Google Scholar 

  • Lee KS, Frank S, Vanderklish P, Arai A, Lynch G (1991) Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci USA 88: 7233–7237

    Article  PubMed  CAS  Google Scholar 

  • Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, Agid Y, Hof PR (1996) Immunohistochemical analysis of the iron binding protein lactotransferrin in the mesencephalon of Parkinson’s disease cases. Acta Neuropathol 91: 566–572

    Article  PubMed  CAS  Google Scholar 

  • Manaye KF, Sonsalla PK, Brooks BA, German DC (1991) Calbindin-28k is located in the midbrain dopaminergic neurons which are resistant to MPTP-induced degeneration. Soc Neurosci Abstr 17: 1275

    Google Scholar 

  • Mouatt-Prigent A, Agid Y, Hirsch EC (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson’s disease? Brain Res 668: 62–70

    Article  PubMed  CAS  Google Scholar 

  • Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased m-calpain expression in the mesencephalon of patients with Parkinson’s disease but not in other neurodegenerative disorders involving the mesencephalon: a role in cell death? Neuroscience 73: 979–987

    Article  PubMed  CAS  Google Scholar 

  • Nilsson E, Alafuzoff I, Blennow K, Blomgren K, Hall C M, Janson I, Karlsson I, Wallin A, Gottfries CG, Karlsson JO (1990) Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging 11: 425–431

    Article  PubMed  CAS  Google Scholar 

  • Nixon RA, Quackenbush R, Vitto A (1986) Multiple calcium-activated neutral proteinases (CANP) in mouse retinal ganglion cell neurons: specificities for endogenous neuronal substrates and comparison to purified brain CANP. J Neurosci 6:1252–1263

    PubMed  CAS  Google Scholar 

  • Ostwald K, Hagberg H, Andine P, Karlsson JO (1993) Up-regulation of calpain activity in neonatal rat brain after hypoxic-ischemia. Brain Res 630: 289–294

    Article  PubMed  CAS  Google Scholar 

  • Rami A, Krieglstein J (1993) Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res 609: 67–70

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520

    Article  PubMed  CAS  Google Scholar 

  • Siman R, Gall C, Perlmuter LS, Christian C, Baudry M, Lynch G (1985) Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain. Brain Res 347: 399–403

    Article  PubMed  CAS  Google Scholar 

  • Yamada T, McGeer PL, Baimbridge KG, McGeer P (1990) Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin D28k. Brain Res 26: 303–307

    Article  Google Scholar 

  • Yoshida KI, Sorimachi Y, Fujiwara M, Hironaka K (1995) Calpain is implicated in rat myocardial injury after ischemia or reperfusion. Jpn Circ J 59: 40–48

    Article  PubMed  CAS  Google Scholar 

  • Zhang P, Anglade P, Hirsch EC, Javoy-Agid F, Agid Y (1994) Distribution of manganese dependent superoxide dismutase in the human brain. Neuroscience 61: 317–330

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Dr. Etienne C. Hirsch

    Present address: INSERM U289, Hôpital de la Salpêtrière, 47 Boulevard de l’Hôpital, F-75013, Paris, France

Authors and Affiliations

  1. INSERM U289, Hôpital de la Salpêtrière, 47 Boulevard de l’Hôpital, F-75013, Paris, France

    B. Faucheux, P. Damier, A. Mouatt-Prigent & Y. Agid

Authors
  1. Dr. Etienne C. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Faucheux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Damier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Mouatt-Prigent
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Agid
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry, University of Würzburg, Germany

    P. Riederer

  2. Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada

    D. B. Calne

  3. Clinical Research, Schering AG, Berlin, Germany

    R. Horowski

  4. Department of Neurology, Juntendo University, Tokyo, Japan

    Y. Mizuno

  5. Department of Neurology, University of Innsbruck, Austria

    W. Poewe

  6. Faculty of Medicine, Institute of Pharmacology, Technion — Israel Institute of Technology, Haifa, Israel

    M. B. H. Youdim

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Wien

About this paper

Cite this paper

Hirsch, E.C., Faucheux, B., Damier, P., Mouatt-Prigent, A., Agid, Y. (1997). Neuronal vulnerability in Parkinson’s disease. In: Riederer, P., Calne, D.B., Horowski, R., Mizuno, Y., Poewe, W., Youdim, M.B.H. (eds) Advances in Research on Neurodegeneration. Journal of Neural Transmission. Supplementa, vol 50. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6842-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6842-4_9

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82898-4

  • Online ISBN: 978-3-7091-6842-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation